Participated · Equity · Dec 2024

Saventic Health, founded in 2019 and based in Warsaw, develops AI algorithms to assist clinicians in diagnosing rare diseases. Its technology analyzes medical records and currently has 50 algorithms in use, enabling diagnoses of over 200 individuals in the past year. Solutions are deployed globally through projects with 11 of the 30 largest pharmaceutical companies and more than 30 clinics and hospitals across Poland, Germany, France, Brazil, and Canada. The 40-member team of doctors, data scientists, and data engineers focuses on leveraging AI for healthcare innovation, with algorithms registered as medical devices across the EU and certified as medical products in parts of South America. The company says its approach identifies potential rare disease diagnoses more efficiently than traditional methods, which can take 7–12 years and have low success rates. Saventic is pursuing geographic expansion into additional European and South American markets and plans to enter the U.S. after completing a forthcoming Series A.

Participated · Equity · Dec 2023

Wealthon builds an all-in-one multi-product platform for SMEs that combines POS, lending, payments and financial-management tools. Its core solutions include POSCASH (repayments tied to payment-terminal transactions), WALLET (a mobile wallet), LIMIT (instant credit line) and a POS system with order and inventory management. Founded in 2019 and based in Warsaw, the company began as a lending platform and has expanded into an integrated SME financial-services ecosystem. In 2024 Wealthon tripled the volume of financing it provided year-over-year, reporting a gross merchandise value (GMV) of €118.3 million. The company plans further product development, sales-network strengthening, potential acquisitions and international expansion. The recent funding is intended to support scaling its multi-product offering across HoReCa, retail, e-commerce and other SME segments. Wealthon offers financing and entrepreneurial tools to small and medium-sized enterprises, led by CEO Aleksander Majchrzak. Its core product, the Wealthon Poscash loan, uses a proprietary scoring system to assess creditworthiness and delivers automatic decisions quickly. Repayments on Poscash depend on daily turnover at the customer’s payment terminal. In May the company partnered with IdoSell to create financing dedicated to e-commerce stores. Wealthon secured debt financing of USD 12.3M from funds managed by CVI Dom Maklerski. The company plans to use the funds to scale the business, develop additional financial products, and expand in the e-commerce sector. Wealthon focuses on providing financial services for entrepreneurs, with a core product of lending to microenterprises that often fall outside traditional banks' offerings. The company raised 32 mln zł to accelerate the development of its financial services. Proceeds will fund dynamic growth and the buildout of a broader ecosystem of products for firms. Wealthon says the funding will support expansion of its crediting operations for small businesses. The company referenced plans for 2024 in an article in Puls Biznesu but did not disclose detailed targets in the text provided.

Participated · Seed · Aug 2022

Talkie.ai develops an AI platform that automates telephone hotlines for healthcare organisations, offering voicebots for appointment booking, prescription orders, basic triage and integration with appointment and call-centre systems. Its product emphasizes rapid deployment and no-code configuration, with implementations ranging from one day to several weeks and an admin panel for full user control. The company reports its bots handle about 80% of customer inquiries and can cut call-centre operating costs by up to half; its voicebots achieve over 90% accuracy in understanding caller intent after just the first 10 data samples. Talkie.ai also uses voice cloning to make interactions more natural and offers both standard industry-specific solutions and fully customisable deployments. Founded in 2018 and operating in Poland, the UK and the US, the startup already derives more than a third of its revenue from the US. The new funding will be used to further specialise the healthcare offering, accelerate US expansion, grow the team and introduce off-the-shelf products for other industries.